Advisory Services Network adds AtriCure (ATRC) to its portfolio

AtriCure (ATRC) : Advisory Services Network added new position in AtriCure during the most recent quarter end. The investment management firm now holds 16,414 shares of AtriCure which is valued at $287,573 , the company said in a statement filed on Oct 7, 2016 with the SEC.AtriCure makes up approximately 0.05% of Advisory Services Network’s portfolio.

Other Hedge Funds, Including , Bnp Paribas Arbitrage Sa boosted its stake in ATRC in the latest quarter, The investment management firm added 1,032 additional shares and now holds a total of 2,254 shares of AtriCure which is valued at $35,996.

AtriCure opened for trading at $16.22 and hit $17.69 on the upside on Friday, eventually ending the session at $17.52, with a gain of 8.48% or 1.37 points. The heightened volatility saw the trading volume jump to 4,13,793 shares. Company has a market cap of $582 M.

On the company’s financial health, AtriCure reported $-0.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.30. The company had revenue of $39.70 million for the quarter, compared to analysts expectations of $39.84 million. The company’s revenue was up 21.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.18 EPS.

AtriCure Inc. is a medical device company providing atrial fibrillation (Afib) solutions. The Company has three primary product lines for cardiac tissue ablation and a product line for left atrial appendage exclusion. The Company’s Isolator Synergy System which includes its Isolator Synergy clamps generator and switchbox is used for the treatment of persistent and long-standing persistent Afib in patients who are undergoing open concomitant coronary artery bypass grafting and valve replacement or repair. The cryoICE cryosurgery product line offers a range of both single use and reusable cryoablation devices. The AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart’s left atrial appendage (LAA). Its radiofrequency (RF) ablation products are indicated for the ablation of cardiac tissue. The Company sells enabling technologies including its Lumitip dissectors and Endoscopic Technologies Inc.’s (Estech) line of reusable cardiac surgery instruments.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

AtriCure - Is it time to Sell?

Top Brokerage Firms are advising their investors on AtriCure. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.